Mycophenolate blood level monitoring: Recent progress: Minireview

American Journal of Transplantation

Volumn 9, Issue 7, 2009, Pages 1495-1499

  Van Gelder, T ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Monitoring; Mycophenolate mofetil; Mycophenolic acid; Pharmacology; Therapeutic drug monitoring

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; MYCOPHENOLIC ACID; PREDNISONE;

ACUTE GRAFT REJECTION; AREA UNDER THE CURVE; AUTOIMMUNE DISEASE; BLOOD TOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; GASTROINTESTINAL SYMPTOM; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOADING DRUG DOSE; PRIORITY JOURNAL; SHORT SURVEY;

DRUG MONITORING; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67649649426     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02678.x     Document Type: Short Survey

References (24)

1. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 2008 85 : 1675 1685.
2. de Winter BC, van Gelder T, Glander P et al. Population pharmacokinetics of mycophenolic acid : A comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. Clin Pharmacokinet 2008 47 : 827 838.
3. van Hest RM, van Gelder T, Bouw R et al. Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol 2007 63 : 741 752. (Pubitemid 46753575)
4. van Hest RM, van Gelder T, Vulto AG, Mathot RA. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet 2005 44 : 1083 1096. (Pubitemid 41356393)
5. Le Guellec C, Bourgoin H, Büchler M et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet 2004 43 : 253 266. (Pubitemid 38429305)
6. van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: A population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006 17 : 871 880.
7. Hesselink DA, van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther 2005 78 : 317 321. (Pubitemid 41393666)
8. Van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999 68 : 261 266. (Pubitemid 29360288)
9. Weber LT, Shipkova M, Armstrong VW et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002 13 : 759 768. (Pubitemid 34183943)
10. Ekberg H, Grinyó J, Nashan B et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant 2007 7 : 560 570. (Pubitemid 46376436)
11. Atcheson BA, Taylor PJ, Mudge DW et al. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol 2005 59 : 271 280. (Pubitemid 40388081)
12. Dost D, van Leerdam ME, van Dekken H et al. Crohn's-like enterocolitis associated with mycophenolic acid treatment. Gut 2008 57 : 1330.
13. Heller T, van Gelder T, Budde K et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am J Transplant 2007 7 : 1822 1831. (Pubitemid 46905448)
14. Pisupati J, Jain A, Burckart G et al. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 2005 45 : 34 41.
15. Tredger JM, Brown NW, Adams J et al. Monitoring mycophenolate in liver transplant recipients: Toward a therapeutic range. Liver Transpl 2004 10 : 492 502. (Pubitemid 38443588)
16. Meiser BM, Pfeiffer M, Schmidt D et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: Importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999 18 : 143 149. (Pubitemid 29159294)
17. Yamani MH, Starling RC, Goormastic M et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation 2000 69 : 2326 2330. (Pubitemid 30408997)
18. DeNofrio D, Loh E, Kao A et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. Heart Lung Transplant 2000 19 : 1071 1076. (Pubitemid 30834131)
19. Neumann I, Fuhrmann H, Fang IF, Jaeger A, Bayer P, Kovarik J. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrol Dial Transplant 2008 23 : 3514 3520.
20. de Winter BC, van Gelder T. Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseases. Nephrol Dial Transplant 2008 23 : 3386 3388.
21. Le Meur Y, Büchler M, Thierry A et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007 7 : 2496 2503. (Pubitemid 47566324)
22. van Gelder T, Silva HT, de Fijter JW et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: The fixed-dose concentration-controlled trial. Transplantation 2008 86 : 1043 1051.
23. Bloom R, Kaplan B, Meier-Kriesche HU et al. Opticept trial: Efficacy and safety of monitored MMF in combination with CNI in renal transplantation at 1 and 2 years. Transplantation 2008 86 (Suppl 301 (Abstract 862).
24. Pescovitz MD, Conti D, Dunn J et al. Intravenous mycophenolate mofetil: Safety, tolerability, and pharmacokinetics. Clin Transplant 2000 14 : 179 188. (Pubitemid 30242951)